SILVER SPRING, Maryland, June 11, 2026
The U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for generic Nitenpyram Tablets, marking the first generic animal drug authorized for the treatment of New World Screwworm (NWS) infestations in dogs and cats. The authorization represents a significant milestone in the U.S. government’s ongoing efforts to contain and eradicate the destructive parasite, which poses a serious threat to animal health. The emergency authorization allows the over-the-counter use of nitenpyram in dogs, puppies, cats, and kittens that are at least four weeks old and weigh a minimum of two pounds. Regulatory officials stated that the decision was based on scientific evidence demonstrating that the treatment may effectively eliminate NWS larvae while providing a favorable benefit-risk profile. The move adds an affordable and rapidly acting treatment option to the growing arsenal of veterinary tools being deployed to combat the expanding screwworm threat across affected regions.
Emergency Authorization Expands Veterinary Response to NWS Threat
New World Screwworm remains one of the most damaging parasitic threats affecting mammals, including companion animals, livestock, and wildlife. The parasite originates when adult flies deposit eggs into open wounds or mucous membranes. After hatching, the larvae rapidly burrow into living tissue, causing severe injury, infection, and potentially life-threatening complications if left untreated. The FDA noted that while the overall risk remains low for most pets in the United States, animals recently located in regions with confirmed NWS activity face elevated exposure risk. Under the authorization, Nitenpyram Tablets can be administered as an emergency treatment to rapidly eliminate larvae.
Regulatory authorities emphasized that the authorization forms part of a broader federal strategy involving multiple agencies working together to prevent the spread of the pest. Since the emergency declaration was first issued in 2025, regulators have accelerated the review of veterinary countermeasures, resulting in numerous emergency authorizations and conditional approvals aimed at strengthening national preparedness against NWS outbreaks.
Nitenpyram Provides Rapid Action Against Screwworm Larvae
Advertisement
Nitenpyram is a fast-acting veterinary medication that works by targeting and killing New World Screwworm larvae within hours of administration. According to the FDA, most larvae are eliminated shortly after the initial dose, with a second dose recommended six hours later to maximize treatment effectiveness. The product is available in 11.4 mg and 57 mg tablet strengths, with dosing determined according to the animal’s body weight. Although the medication effectively treats active infestations, officials stressed that it does not prevent future infestations or provide long-term protection against reinfection.
Veterinary professionals may still need to remove remaining larvae and provide wound management to minimize the risk of infection and tissue damage. Pet owners are encouraged to seek veterinary guidance following treatment to ensure proper recovery and implement measures that reduce the likelihood of reinfestation. The availability of a generic product is expected to improve accessibility while supporting emergency response efforts in affected areas.
Strengthening Animal Health Preparedness Through Regulatory Action
The authorization highlights the increasing importance of rapid regulatory action in protecting animal health against emerging biological threats. FDA officials stated that expanding access to generic veterinary medicines strengthens supply chain resilience while providing veterinarians and pet owners with additional treatment options during emergency situations. The agency concluded that the known and potential benefits of Nitenpyram outweigh the identified risks based on currently available scientific evidence. Industry experts note that the approval of a generic over-the-counter treatment could play a critical role in limiting the impact of future outbreaks by enabling faster intervention before infestations become severe.
As federal agencies continue monitoring the spread of New World Screwworm and evaluating additional treatment options, the authorization underscores a broader commitment to safeguarding companion animals, livestock populations, and agricultural systems. The latest regulatory action reinforces the role of science-driven veterinary innovation in supporting national animal health security and ensuring preparedness against evolving parasitic threats.
Source: FDA press release
